Power3 and The Methodist Hospital Research Institute form collaborative research agreement for neurodegenerative disease blood test serum proteins.

Power3 Medical Products, Inc. (The Woodlands, TX) entered into a research agreement with The Methodist Hospital Research Institute to search for biomarkers and develop a suite of tests that directly impact the diagnosis of neurodegenerative diseases. Power3, in collaboration with Stan Appel, M.D., Chair of Neurology at the Methodist Neurological Institute, has completed clinical validation, testing serum proteins from over 600 patients, normal and neurodegenerative disease controls, including patients with Lou Gehrig's (ALS), Alzheimer's and Parkinson's diseases.

The collaborative team has applied the latest proteomic techniques to the differential diagnosis of neurodegenerative diseases utilizing blood serum. Dr. Appel, a renowned and recognized global leader in neuromuscular and neurodegenerative disease research, has been working in concert with Dr. Ira L. Goldknopf, Chief Scientific Officer, and others on the Power3 team to further validate these biomarkers.

"With the signing of this research agreement, we are continuing our collaboration with Dr. Stan Appel and his neurology team at The Methodist Hospital's Neurological Institute," said Steve Rash, Power3 Medical's CEO. "Dr. Appel is the world opinion leader on Lou Gehrig's Disease (ALS) and we are proud of the achievements made to date in our joint efforts to develop early diagnostic and treatment methods for ALS, Alzheimer's and Parkinson's diseases. We look forward to continuing our long and productive relationship with Stan and his team."

According to Dr. Goldknopf, "With this suite of tests, which involve monitoring the concentration of 34 proteins in the blood, we are able to identify unique biomarkers with profiles that appear to distinguish patients with Lou Gehrig's (ALS), Alzheimer's and Parkinson's diseases from one another, as well as from normal patients and patients with other motor neuron and neurological disorders. To our gratification, the specificity and sensitivity of these tests continue to exceed our expectations. In fact, we anticipate filing our second Pre-IDE application with the FDA for a specific test for ALS vs. ALS like disorders in the near term."

Dr. Appel noted, "The proteins identified in conjunction with Power3 represent promising biomarkers for ALS, Alzheimer's and Parkinson's diseases. A main problem to date is that there is a lack of biomarkers and tests for early diagnosis, prognosis, and guidelines for therapy for neurodegenerative diseases. We are pleased with the progress that we have made, and feel these biomarkers and tests offer great promise for improving the clinical outcomes of our patients."

Power3 is proceeding to evaluate serum from additional samples and plans to publish the interesting and promising results later this year.

Power3 Medical Products is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The company's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet

needs in areas such as breast cancer and neurodegenerative disease.

Power3 Medical Products, Inc.

[phone]

www.power3medical.com